Excessive Daytime Sleepiness

A phase 2 study shows samelisant significantly reduces excessive daytime sleepiness in narcolepsy, paving the way for further research and development.

Recent findings from an analysis showed that sodium oxybate significantly reduced narcolepsy symptoms, including cataplexy and excessive daytime sleepiness, among patients with the sleep disorder.

The phase 2, placebo-controlled, crossover trial will test whether 50 mg once daily lorundrostat may relieve the severity of upper airway obstruction and reduce nocturnal hypertension.

Over the 6-month treatment period, patients saw improvements in cataplexy frequency, excessive daytime sleepiness, cognition, and work productivity with AXS-12.